AbbVie : ABBV

All AbbVie Articles

580 Articles

Lee Jackson | Jun 15, 2015 at 9:15 AM EDT

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price…

Chris Lange | Jun 10, 2015 at 8:30 AM EDT

Short Sellers Back Off Big Pharma

The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Trey Thoelcke | Jun 10, 2015 at 6:49 AM EDT

The 6 Most Shorted NYSE Stocks in May

AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15…

Chris Lange | Jun 8, 2015 at 1:00 PM EDT

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical…

Chris Lange | Jun 3, 2015 at 10:30 AM EDT

How Halozyme Will Continue to Grow With Its New Deal

Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.

Chris Lange | Jun 2, 2015 at 8:50 AM EDT

The 4 Overlooked Winners of ASCO

ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across…

Chris Lange | May 28, 2015 at 9:30 AM EDT

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short…

Jon C. Ogg | May 27, 2015 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero, Virtu and More

Wednesday's top analyst upgrades, downgrades and initiations include Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero Energy and Virtu Financial.

Lee Jackson | May 22, 2015 at 9:15 AM EDT

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug…

Chris Lange | May 12, 2015 at 9:50 AM EDT

Short Sellers Keep Strong Bets Against Big Pharma

The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Chris Lange | May 5, 2015 at 10:50 AM EDT

Top Credit Suisse Major Pharma Stock Picks to Buy

Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.

Lee Jackson | Apr 22, 2015 at 8:30 AM EDT

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

A new report from Deutsche Bank highlights all of the known risks and focuses in on stocks that are reasonable…

Lee Jackson | Apr 20, 2015 at 9:10 AM EDT

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising…

Lee Jackson | Mar 16, 2015 at 8:55 AM EDT

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

24/7 Wall St. has found four good examples of blue-chip stocks that got a little tarnished recently for one reason…

1 … 33 34 35 36 37 … 39

AbbVie : ABBV

All AbbVie Articles

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

Short Sellers Back Off Big Pharma

The 6 Most Shorted NYSE Stocks in May

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

How Halozyme Will Continue to Grow With Its New Deal

The 4 Overlooked Winners of ASCO

Short Sellers More Selective on Big Pharma Stocks

Top Analyst Upgrades and Downgrades: Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero, Virtu and More

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Short Sellers Keep Strong Bets Against Big Pharma

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Top Credit Suisse Major Pharma Stock Picks to Buy

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

$10,000 in Asia’s Biggest 50 Stocks Became $15,267 in Five Months: Here’s Why

ICLN’s 45% YTD Surge Marks a Regime Shift: From Policy Bet to Infrastructure Play, With a July Deadline Looming

Forget GLD: GLDM Tracks the Exact Same Bullion at One Quarter the Annual Cost

57% Say They Haven't Saved Enough, and the Data Confirms It

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again

$10,000 in Asia’s Biggest 50 Stocks Became $15,267 in Five Months: Here’s Why

ICLN’s 45% YTD Surge Marks a Regime Shift: From Policy Bet to Infrastructure Play, With a July Deadline Looming

AbbVie : ABBV

All AbbVie Articles

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

Short Sellers Back Off Big Pharma

The 6 Most Shorted NYSE Stocks in May

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

How Halozyme Will Continue to Grow With Its New Deal

The 4 Overlooked Winners of ASCO

Short Sellers More Selective on Big Pharma Stocks

Top Analyst Upgrades and Downgrades: Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero, Virtu and More

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Short Sellers Keep Strong Bets Against Big Pharma

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Top Credit Suisse Major Pharma Stock Picks to Buy

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

$10,000 in Asia’s Biggest 50 Stocks Became $15,267 in Five Months: Here’s Why

ICLN’s 45% YTD Surge Marks a Regime Shift: From Policy Bet to Infrastructure Play, With a July Deadline Looming

Forget GLD: GLDM Tracks the Exact Same Bullion at One Quarter the Annual Cost

Featured Reads

57% Say They Haven't Saved Enough, and the Data Confirms It

Family Limited Partnerships: How to Lock In $4 Million in Valuation Discounts Before Congress Acts Again